Literature DB >> 10024053

Unraveling the mechanisms of neurotoxicity in HIV type 1-associated dementia: inhibition of neuronal synaptic transmission by macrophage secretory products.

H Xiong1, J Zheng, M Thylin, H E Gendelman.   

Abstract

The cognitive and motor impairments of HIV-1-associated dementia (HAD) often result from neuronal damage of drop-out. In the infected human host, virus-infected immune-competent mononuclear phagocytes (MPs) (brain macrophages and microglia) are the target cells for HIV-1 and the producers of bioactive molecules that mediate neural damage. Indeed, in laboratory experiments, activated HIV-1-infected macrophages placed into human or rodent brain tissues induce neuronal apoptosis. Nonetheless, the mechanisms for neuronal dysfunction in HAD have yet to be discerned. To these ends, we studied the effects of HIV-1-infected monocyte-derived macrophage (MDM) secretions, electrophysiologically, on neuronal synaptic transmission. Bath application of HIV-1-infected MDM culture fluids onto rat hippocampal brain slices resulted in inhibition of evoked field excitatory postsynaptic potentials (EPSPs). In contrast, fluids from uninfected MDMs showed mild effects on the EPSPs. HIV-1-associated inhibition of EPSPs was enhanced by LPS activation, both for HIV-1-infected and uninfected MDMs. Importantly, paired-pulse facilitation ratio tests showed that factors secreted by HIV-1-infected MDMs acted transiently on presynaptic terminals, providing insights into the site of action and mechanism of the MDM-induced neuronal dysfunction. These results, taken together, demonstrate that factors produced as a consequence of MDM infection and activation affect neuronal synaptic transmission.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10024053     DOI: 10.1089/088922299311718

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  8 in total

1.  Molecular interactions of human immunodeficiency virus type 1 with primary human oral keratinocytes.

Authors:  Edward A Acheampong; Zahida Parveen; Lois W Muthoga; Vivian Wasmuth-Peroud; Mehrnush Kalayeh; Adnan Bashir; Robert Diecidue; Muhammad Mukhtar; Roger J Pomerantz
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

2.  Human Immunodeficiency virus type 1 Nef potently induces apoptosis in primary human brain microvascular endothelial cells via the activation of caspases.

Authors:  Edward A Acheampong; Zahida Parveen; Lois W Muthoga; Mehrnush Kalayeh; Muhammad Mukhtar; Roger J Pomerantz
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

Review 3.  Neuroprotective strategies for HIV-1 associated dementia.

Authors:  Huanyu Dou; Jeffrey D Kingsley; R Lee Mosley; Harris A Gelbard; Howard E Gendelman
Journal:  Neurotox Res       Date:  2004       Impact factor: 3.911

4.  HIV-1 infected immune competent mononuclear phagocytes influence the pathways to neuronal demise.

Authors:  J Zheng; M R Thylin; Y Persidsky; C E Williams; R L Cotter; W Zink; L Ryan; A Ghorpade; K Lewis; H E Gendelman
Journal:  Neurotox Res       Date:  2001-10       Impact factor: 3.911

Review 5.  Feline immunodeficiency virus neuropathogenesis: from cats to calcium.

Authors:  Rick B Meeker
Journal:  J Neuroimmune Pharmacol       Date:  2006-11-28       Impact factor: 4.147

6.  4-Aminopyridine improves spatial memory in a murine model of HIV-1 encephalitis.

Authors:  James P Keblesh; Huanyu Dou; Howard E Gendelman; Huangui Xiong
Journal:  J Neuroimmune Pharmacol       Date:  2009-05-23       Impact factor: 4.147

7.  Differential regulation of innate and adaptive immune responses in viral encephalitis.

Authors:  Julia D Rempel; Shannon J Murray; Jeffrey Meisner; Michael J Buchmeier
Journal:  Virology       Date:  2004-01-05       Impact factor: 3.616

8.  Mouse hepatitis virus neurovirulence: evidence of a linkage between S glycoprotein expression and immunopathology.

Authors:  Julia D Rempel; Shannon J Murray; Jeffrey Meisner; Michael J Buchmeier
Journal:  Virology       Date:  2004-01-05       Impact factor: 3.616

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.